References
- National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 2. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD 1997, NIH Publication 97‐4051
- Condemi J J, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate vs. increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immun 1999; 82: 383–389
- Greening A, Ind P, Northfield M, Shaw G. Added salmeterol vs. higher‐dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids. Lancet 1994; 344: 219–224
- Murray J J, Church N L, Anderson W H, Bernstein D I, Wenzel S E, Emmett A, Rickard K A. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999; 20(3)173–180
- Pearlman D S, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, Prillaman B, Shah T. Inhaled salmeterol and fluticasone propionate: a study comparing monotherapy and combination therapy in asthma. Ann Allergy, Asthma, Immun 1999; 82(3)257–265
- Shrewsbury S, Pyke S, Britton M. A meta‐analysis of increasing inhaled steroid or adding salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368–1373
- Van Noord J A, Schreurs A J, Mol S J, Mulder P G. Addition of salmeterol vs. doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54(3)207–212
- Vermetten F A, Boermans A J, Luiten W D, Mulder P G, Vermue N A. Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low‐dose inhaled steroids. J Asthma 1999; 36(1)97–106
- Woolcock A, Lundback B, Ringdal N, Jacques L. Comparison of additional of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–1488
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am J Respir Crit Care Med 1995; 152: 77–120
- Report of the working party of the European community for coal and steel. Standardization of lung function tests. Clin Respir Physiol 1983; 19(Suppl 5)1–94
- Polgar G, Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. WB Saunders, Philadelphia, PA 1971; 1–269
- Crapo R, Morris A, Gardner R. Reference values for lung function tests. Respir Care 1989; 34: 626–637
- Shapiro G, Lumry W, Wolfe J, Given J, White M V, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50 µg and fluticasone propionate 250 µg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527–534
- Kavuru M, Melamed J, Gross G, LaForce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double‐blind, placebo‐controlled trial. J Allergy Clin Immunol 2000; 105: 1108–1116
- Neuhauser M, Steinijans V W, Bretz F. The evaluation of multiple clinical endpoints, with application to asthma. Drug Inf J 1999; 33: 471–477
- Partridge M R. Metered‐dose inhalers and CFCs: what respiratory physicians need to know. Respir Med 1994; 88: 645–647
- Woodcock A. Continuing patient care with metered‐dose inhalers. J Aerosol Med 1995; 8(Suppl 20)S5–S10
- Woodcock A. CFCs and inhalers. Lancet 1994; 344: 182–183
- Montreal protocol on substances that deplete the ozone layer. Int Leg Mater 1987; 16: 1541